Cargando…
The Nanoparticle-Enabled Success of COVID-19 mRNA Vaccines and the Promise of Microneedle Platforms for Pandemic Vaccine Response
The coronavirus disease 2019 (COVID-19) public health crisis has reached critical mass, but interdisciplinary research efforts have provided the global community with the first effective medical intervention to fight the pandemic—COVID-19 vaccines. Two of the vaccines approved for use in the United...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mary Ann Liebert, Inc., publishers
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8787697/ https://www.ncbi.nlm.nih.gov/pubmed/34958232 http://dx.doi.org/10.1089/dna.2021.0538 |
_version_ | 1784639411787399168 |
---|---|
author | Kapnick, Senta M. |
author_facet | Kapnick, Senta M. |
author_sort | Kapnick, Senta M. |
collection | PubMed |
description | The coronavirus disease 2019 (COVID-19) public health crisis has reached critical mass, but interdisciplinary research efforts have provided the global community with the first effective medical intervention to fight the pandemic—COVID-19 vaccines. Two of the vaccines approved for use in the United States and Europe deliver nucleic acid in the form of mRNA, the success of which would not be possible without biomaterials. Lipid nanoparticle (LNP)-based mRNA vaccines, discussed in this perspective, protect nucleic acids from degradation and deliver cargo directly to the intracellular compartment of cells where it is translated into the antigenic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein that triggers protective immune responses. Despite success of LNP-based mRNA vaccines thus far, the pandemic has highlighted the need for emerging technologies that enable rapid development and increased accessibility to vaccination. Microneedle arrays, also discussed in this study, provide features that could lower barriers to vaccine access in resource-poor regions. The ability to exchange antigens within arrays could also facilitate swift vaccine deployment as public health needs evolve (e.g., in response to SARS-CoV-2 variants or entirely new pathogens). Therefore, the COVID-19 pandemic has spotlighted the readiness and value of biomaterials for the prevention and management of disease outbreaks. |
format | Online Article Text |
id | pubmed-8787697 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Mary Ann Liebert, Inc., publishers |
record_format | MEDLINE/PubMed |
spelling | pubmed-87876972022-01-25 The Nanoparticle-Enabled Success of COVID-19 mRNA Vaccines and the Promise of Microneedle Platforms for Pandemic Vaccine Response Kapnick, Senta M. DNA Cell Biol Section B: Infectious Diseases: Pathogenesis, Immune Responses, Vaccines, Diagnostics, and the Broad Impact of Them on Society The coronavirus disease 2019 (COVID-19) public health crisis has reached critical mass, but interdisciplinary research efforts have provided the global community with the first effective medical intervention to fight the pandemic—COVID-19 vaccines. Two of the vaccines approved for use in the United States and Europe deliver nucleic acid in the form of mRNA, the success of which would not be possible without biomaterials. Lipid nanoparticle (LNP)-based mRNA vaccines, discussed in this perspective, protect nucleic acids from degradation and deliver cargo directly to the intracellular compartment of cells where it is translated into the antigenic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein that triggers protective immune responses. Despite success of LNP-based mRNA vaccines thus far, the pandemic has highlighted the need for emerging technologies that enable rapid development and increased accessibility to vaccination. Microneedle arrays, also discussed in this study, provide features that could lower barriers to vaccine access in resource-poor regions. The ability to exchange antigens within arrays could also facilitate swift vaccine deployment as public health needs evolve (e.g., in response to SARS-CoV-2 variants or entirely new pathogens). Therefore, the COVID-19 pandemic has spotlighted the readiness and value of biomaterials for the prevention and management of disease outbreaks. Mary Ann Liebert, Inc., publishers 2022-01-01 2022-01-12 /pmc/articles/PMC8787697/ /pubmed/34958232 http://dx.doi.org/10.1089/dna.2021.0538 Text en © Senta M. Kapnick 2022; Published by Mary Ann Liebert, Inc. https://creativecommons.org/licenses/by/4.0/This Open Access article is distributed under the terms of the Creative Commons License [CC-BY] (http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Section B: Infectious Diseases: Pathogenesis, Immune Responses, Vaccines, Diagnostics, and the Broad Impact of Them on Society Kapnick, Senta M. The Nanoparticle-Enabled Success of COVID-19 mRNA Vaccines and the Promise of Microneedle Platforms for Pandemic Vaccine Response |
title | The Nanoparticle-Enabled Success of COVID-19 mRNA Vaccines and the Promise of Microneedle Platforms for Pandemic Vaccine Response |
title_full | The Nanoparticle-Enabled Success of COVID-19 mRNA Vaccines and the Promise of Microneedle Platforms for Pandemic Vaccine Response |
title_fullStr | The Nanoparticle-Enabled Success of COVID-19 mRNA Vaccines and the Promise of Microneedle Platforms for Pandemic Vaccine Response |
title_full_unstemmed | The Nanoparticle-Enabled Success of COVID-19 mRNA Vaccines and the Promise of Microneedle Platforms for Pandemic Vaccine Response |
title_short | The Nanoparticle-Enabled Success of COVID-19 mRNA Vaccines and the Promise of Microneedle Platforms for Pandemic Vaccine Response |
title_sort | nanoparticle-enabled success of covid-19 mrna vaccines and the promise of microneedle platforms for pandemic vaccine response |
topic | Section B: Infectious Diseases: Pathogenesis, Immune Responses, Vaccines, Diagnostics, and the Broad Impact of Them on Society |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8787697/ https://www.ncbi.nlm.nih.gov/pubmed/34958232 http://dx.doi.org/10.1089/dna.2021.0538 |
work_keys_str_mv | AT kapnicksentam thenanoparticleenabledsuccessofcovid19mrnavaccinesandthepromiseofmicroneedleplatformsforpandemicvaccineresponse AT kapnicksentam nanoparticleenabledsuccessofcovid19mrnavaccinesandthepromiseofmicroneedleplatformsforpandemicvaccineresponse |